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ABSTRACT
Background. Bevacizumab, a VEGF-A inhibitor, in combina-
tion with chemotherapy, has proven to increase progression-
free survival (PFS) and overall survival in multiple lines of
therapy of metastatic colorectal cancer (mCRC). The angio-
genic factor angiopoetin-2 (Ang-2) is associated with poor
prognosis in many cancers, including mCRC. Preclinical
models demonstrate improved activity when inhibiting both
VEGF-A and Ang-2, suggesting that the dual VEGF-A and
Ang-2 blocker vanucizumab (RO5520985 or RG-7221) may
improve clinical outcomes. This phase II trial evaluated the
efﬁcacy of vanucizumab plus modiﬁed (m)FOLFOX-6 (folinic
acid (leucovorin), ﬂuorouracil (5-FU) and oxaliplatin) versus
bevacizumab/mFOLFOX-6 for ﬁrst-line mCRC.
Patients and Methods. All patients received mFOLFOX-6
and were randomized 1:1 to also receive vanucizumab
2,000 mg or bevacizumab 5 mg/kg every other week.
Oxaliplatin was given for eight cycles; other agents were
continued until disease progression or unacceptable toxicity
for a maximum of 24 months. The primary endpoint was
investigator-assessed PFS.
Results. One hundred eighty-nine patients were random-
ized (vanucizumab, n = 94; bevacizumab, n = 95). The num-
ber of PFS events was comparable (vanucizumab, n = 39;
bevacizumab, n = 43). The hazard ratio was 1.00 (95% conﬁ-
dence interval, 0.64–1.58; p = .98) in a stratiﬁed analysis
based on number of metastatic sites and region. Objective
response rate was 52.1% and 57.9% in the vanucizumab
and bevacizumab arm, respectively. Baseline plasma Ang-2
levels were prognostic in both arms but not predictive for
treatment effects on PFS of vanucizumab. The incidence of
adverse events of grade ≥3 was similar between treatment
arms (83.9% vs. 82.1%); gastrointestinal perforations (10.8%
vs. 8.4%) exceeded previously reported rates in this setting.
Hypertension and peripheral edema were more frequent in
the vanucizumab arm.
Conclusion. Vanucizumab/mFOLFOX-6 did not improve PFS
and was associated with increased rates of antiangiogenic
toxicity compared with bevacizumab/mFOLFOX-6. Our
results suggest that Ang-2 is not a relevant therapeutic tar-
get in ﬁrst-line mCRC. The Oncologist 2020;25:e451–e459
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Implications for Practice: This randomized phase II study demonstrates that additional angiopoietin-2 (Ang-2) inhibition
does not result in superior beneﬁt over anti–VEGF-A blockade alone when each added to standard chemotherapy. More-
over, the performed pharmacokinetic and pharmacodynamic analysis revealed that vanucizumab was bioavailable and
affected its intended target, thereby strongly suggesting that Ang-2 is not a relevant therapeutic target in the clinical setting
of treatment-naïve metastatic colorectal cancer. As a result, the further clinical development of the dual VEGF-A and Ang-2
inhibitor vanucizumab was discontinued.
INTRODUCTION
Colorectal cancer (CRC) is a leading cause of cancer deaths in
the Western world [1]. Current ﬁrst- and second-line thera-
pies for metastatic CRC (mCRC) include a range of oxaliplatin-
and irinotecan-based chemotherapy regimens; improved
outcomes have been demonstrated with chemotherapy com-
bined with therapies targeting the EGFR or VEGF-A–VEGFR
signaling pathways [2]. The addition of bevacizumab, a
recombinant humanized anti−VEGF-A monoclonal antibody,
to standard chemotherapy improves both overall survival
(OS) and progression-free survival (PFS), as well as response
rates [3], providing a rationale to explore further treatment
options that target angiogenic pathways.
Angiopoietin-2 (Ang-2) is overexpressed and is a nega-
tive prognostic factor in many cancers, including CRC [4].
High serum Ang-2 levels promote metastatic growth in pre-
clinical models [5] and are associated with poor survival
outcomes in patients [6]. Tumor Ang-2 overexpression is
associated with lymph node metastasis, venous invasion,
and high microvascular density in CRC [7].
Vanucizumab (RO5520985 or RG-7221) is a bispeciﬁc
monoclonal antibody based on a human IgG1 framework,
comprising two different heavy chains and two different
light chains; one arm targets Ang-2 and the other arm
VEGF-A. Vanucizumab showed potent tumor growth inhibi-
tion in a panel of human tumor xenograft models [8] with
superior antitumor activity in larger tumors compared with
the monospeciﬁc antibodies, supporting the notion that
larger tumors exhibit different vessel types that do not all
respond equally to anti–VEGF-A therapy [9]. The observed
clinical safety proﬁle of single-agent vanucizumab was con-
sistent with that reported for selective inhibitors of the
VEGF-A and angiopoietin-Tie2 signaling pathway and
showed encouraging antitumor activity in a heterogeneous
patient population [10]. The purpose of the current study,
also known as BP29262 or the McCAVE trial, was to deter-
mine if concurrent target inhibition of the VEGF-A and
Ang-2 axis by adding vanucizumab to standard chemother-
apy can improve the treatment outcome versus bevacizumab
plus chemotherapy in treatment-naïve patients with mCRC.
PATIENTS AND METHODS
Participants
Adult patients (aged ≥18 years) with histologically or cyto-
logically conﬁrmed mCRC who had not been previously
treated with chemotherapy for metastatic disease and who
were not candidates for surgical resection were eligible for
inclusion. Patients had to have at least one measurable
metastatic lesion, as deﬁned by RECIST version 1.1 [11]. All
patients had an Eastern Cooperative Oncology Group per-
formance status (ECOG PS) of ≤1. Patients were excluded
for any serious or uncontrolled medical disorders and any
prior systemic cancer therapy before day 1 of cycle 1 or
radiotherapy within 28 days prior to day 1 of cycle 1. Patients
who received prior systemic adjuvant therapy for CRC were
excluded if the time interval from last administration of adju-
vant therapy until disease progression was less than
12 months from screening. Additional exclusion criteria
included signiﬁcant cardio- or cerebrovascular disease within
6 months of enrollment, history of abdominal or tracheo-
esophageal ﬁstula, gastrointestinal (GI) perforation or intra-
abdominal abscess, clinical signs or symptoms of GI obstruc-
tion, history of pulmonary hemorrhage with National Cancer
Institute Common Terminology Criteria for Adverse Events
(NCI CTCAE) grade ≥2, or gross hemoptysis.
Study Design and Treatment
The study was conducted in accordance with the principles
of the Declaration of Helsinki and Good Clinical Practice. All
patients provided written informed consent as approved by
local institutional review boards.
McCAVE (ClinicalTrials.gov identiﬁer: NCT02141295) was
a multicenter phase II trial conducted in two phases: a
single-arm, open label safety run-in part followed by a ran-
domized, double-blind parallel group study. Patients in the
safety run-in phase received vanucizumab 2,000 mg followed
by modiﬁed (m)FOLFOX-6 (folinic acid (leucovorin), ﬂuoro-
uracil (5-FU) and oxaliplatin) every two weeks (q2w) for at
least two cycles to ascertain safety of the vanucizumab/
mFOLFOX-6 combination. In the double-blind phase, eligible
patients were randomized in a 1:1 ratio to receive either van-
ucizumab/mFOLFOX-6 or bevacizumab/mFOLFOX-6 (supple-
mental online Table 1). Patients were stratiﬁed prospectively
by region (U.S. vs. rest of world [RoW]) and number of meta-
static sites (one vs. more than one). Study treatment con-
sisted of induction and maintenance therapy that was given
in cycles q2w. Induction therapy comprised eight cycles of
mFOLFOX-6 plus either vanucizumab or bevacizumab.
Patients could switch to maintenance therapy earlier if
oxaliplatin was not tolerated. After induction therapy,
oxaliplatin administration was discontinued and patients
received 5-ﬂuorouracil (5-FU)/folinic acid plus either van-
ucizumab or bevacizumab as maintenance therapy for a max-
imum period of 24 months unless treatment was stopped
earlier because of disease progression, unacceptable toxicity,
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investigator decision, or consent withdrawal. Patients who
stopped chemotherapy, either in part or in whole, could con-
tinue on vanucizumab or bevacizumab for a maximum of
24 months. Dose adjustments were prohibited for van-
ucizumab or bevacizumab but were allowed for mFOLFOX-6
as clinically indicated.
Study Endpoints
The primary endpoint was PFS deﬁned as the time from ran-
domization to the date of ﬁrst documented occurrence of
progression based on RECIST version 1.1 criteria, as deter-
mined by the investigator, or death from any cause on study,
whichever occurred ﬁrst. Death on study was deﬁned as
death from any cause within 30 days of the last study treat-
ment. Patients without an event on study were censored at
the date of the last tumor assessment when the patient was
known to be progression free either during follow-up to initi-
ation of a new cancer treatment, or during study treatment.
Patients without any postbaseline assessments or with all
postbaseline assessments having unknown result or response
but known to be alive at the clinical cutoff for the analysis
were censored at the date of randomization plus 1 day. Sec-
ondary endpoints included overall response rate (ORR) and
OS; OS was calculated from the time from randomization
until death from any cause. The safety and efﬁcacy analyses
were based on the randomized portion of this study only.
Assessments
All tumor lesions were assessed by contrast-enhanced com-
puted tomography (CT) or magnetic resonance imaging (MRI)
scans and read by the local investigator. No independent, cen-
tral review of imaging scans was performed. Tumor response
and progression were assessed according to RECIST 1.1, with
scans repeated every 8 weeks and at the end of study visit. If
a patient discontinued therapy for reasons other than pro-
gression, the patient was followed by regular CT or MRI
assessments until documentation of progressive disease (PD),
initiation of another anticancer therapy, withdrawal of con-
sent, or death. In the event of stable disease (SD), follow-up
assessments had to have met the RECIST version 1.1 SD
criteria at least once after study entry at a minimum interval
of 8 weeks from treatment start. Lesions previously treated
with radiotherapy were not used as target lesions for tumor
assessment. Safety was assessed per NCI CTCAE version 4.03
and routine clinical laboratory assessments continuously
throughout treatment and for 30 days after last dose of treat-
ment. While the study was ongoing, patients were followed
up for subsequent anticancer therapy and survival (e.g., by
phone call) every 3 months until death, loss to follow-up, or
study termination, whichever occurred ﬁrst.
Statistical Analyses
For the safety run-in part, a minimum of six patients was
considered sufﬁcient to determine the safety and tolerability
of the vanucizumab/mFOLFOX-6 combination. The emphasis
of the efﬁcacy analysis was the magnitude of treatment
effect rather than hypothesis testing. Accordingly, the study
was designed to allow detection of a meaningful beneﬁt of
vanucizumab/mFOLFOX-6 versus bevacizumab/mFOLFOX-6.
Based on a total of 80 PFS events observed in the two
treatment arms combined, there was an 80% power to
detect a hazard ratio (HR) of 0.574 at a type I error of 0.05.
Primary and secondary efﬁcacy analyses included all patients
who were randomized and received any dose of study treat-
ment with patients assigned to the treatment arm to which
they were randomized. The safety analysis population
included all patients who had received at least one dose of
study treatment (vanucizumab or bevacizumab) with patients
assigned to the treatment arm, based on treatment actually
received. Kaplan-Meier methods were used to estimate
median PFS for each treatment arm. Stratiﬁcation factors
applied included number of metastatic sites (one vs. more
than one) and region (U.S. vs. RoW). The stratiﬁed Cox pro-
portional hazard model was used to estimate the hazard
ratio and the corresponding 95% conﬁdence interval. Addi-
tional stratiﬁed and nonstratiﬁed sensitivity analyses were
performed using a deﬁnition of PFS including deaths occur-
ring more than 30 days after the last dose of the study drug.
RESULTS
Baseline Characteristics and Patient Disposition
Patients were enrolled into the study from June 2014 to May
2016 at 39 sites in the U.S., European Union, and Australia.
Eight patients took part in the safety run-in part, whereas a
total of 189 patients participated in the randomized part
(vanucizumab, n = 94; bevacizumab, n = 95). One patient
was randomized to vanucizumab but received only chemo-
therapy before being withdrawn from study. The clinical data
cutoff for the primary analysis based on 82 PFS events was
July 29, 2016, providing a median follow-up time of
17.6 months (range 2.8–20.7). The median number of cycles
of vanucizumab or bevacizumab was 12.0 (range 1–47).
Approximately half of the patients were aged more than
65 years. Relevant prognostic factors, including RAS and
BRAF V600E status and tumor sidedness, were largely bal-
anced between arms (Table 1). The main reason for with-
drawal from the study in both treatment arms was PD.
A higher proportion of patients withdrew because of PD in
the bevacizumab arm compared with the vanucizumab arm
(n = 38; 40.0% vs. n = 29; 31.2%). Other reasons for with-
drawal included physician decision (n = 16; 17.2% in the van-
ucizumab arm vs. n = 12; 12.6% in the bevacizumab arm),
adverse events (AEs; n = 16; 17.2% vs. n = 10; 10.5%), with-
drawal of consent (n = 9; 9.7% vs. n = 4; 4.2%), and with-
drawn as a result of study termination or noncompliance
(n = 1 in the bevacizumab arm and n = 1 in the vanucizumab
arm, respectively; supplemental online Fig. 1).
Efﬁcacy
There was no difference in median PFS between the two
treatment arms. The stratiﬁed HR was 1.00 (95% conﬁdence
interval [CI], 0.64–1.58; log-rank p = .98); the median duration
of PFS in the vanucizumab and bevacizumab arms was com-
parable at 343 days (95% CI, 312.0–386.0) versus 334 days
(95% CI, 282.0–390.0), respectively. Similarly, the number of
PFS events was comparable across the vanucizumab and
bevacizumab arms (n = 39; 41.5% vs. n = 43; 45.3%). The
results of the nonstratiﬁed analysis were similar to those of
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the stratiﬁed analysis (HR, 1.03; 95% CI, 0.67–1.59; log-rank
p = .89). The overlapping Kaplan-Meier curves of PFS based
on investigator assessment are shown in Figure 1. Further
exploratory PFS analyses revealed no signiﬁcant differences
between the treatment arms for patient subgroups deﬁned
by prior adjuvant therapy, primary tumor sidedness, ECOG PS,
or BRAF- and RAS- mutation status (Fig. 2). Subgroup analysis
for KRAS and NRAS mutated tumors was consistent with PFS
outcome for all mutant RAS (data not shown). The proportion
of missing RAS data was approximately 15% (28/189). The
investigator-assessed ORR was comparable between the van-
ucizumab and bevacizumab arms, respectively: n = 49, 52.1%
(95% CI, 42.0–62.2) versus n = 55, 57.9% (95% CI, 48.0–67.8;
supplemental online Table 2). At the ﬁnal analysis (data cut-
off February 1, 2017), the OS data were immature. There
were 24 (25.5%) deaths in the vanucizumab arm and
27 (28.4%) deaths in the bevacizumab arm. After the spon-
sor’s decision to terminate the study, the remaining ongoing
patients were discontinued, and no further data on subse-
quent therapies after progression and survival were collected
after the last patient last visit. As a result, no further analyses
were performed.
Pharmacokinetics and Biomarkers
Systemic exposure of vanucizumab was assessed by
noncompartmental and population pharmacokinetic (PK)
analysis and was consistent with that seen after single-
agent administration of vanucizumab [10] (data not shown).
Likewise, PK parameters for oxaliplatin (total and free) and
5-FU were also similar to the ones previously reported [12].
Soluble Ang-2 was assessed by use of a fully validated
method [13] for its potential as a candidate prognostic and
predictive marker. Ang-2 at baseline could be assessed for
184 patients. Patients were classiﬁed as Ang-2 higher
(“high”) or Ang-2 lower or equal (“low”) based on the base-
line, median Ang-2 plasma concentration level as the
prespeciﬁed cutoff point. Baseline Ang-2 plasma levels were
prognostic but not predictive for PFS (Fig. 3). In both arms,
patients with high baseline Ang-2 plasma levels had a worse
outcome compared with patients with low levels. The non-
stratiﬁed PFS HR (all deaths) comparing low versus high
baseline Ang-2 levels was similar in each arm (vanucizumab
HR 0.74 [95% CI, 0.39–1.40]; bevacizumab HR 0.67 [95% CI,
0.38–1.18]). Likewise, the HRs comparing treatment with
vanucizumab versus bevacizumab were similar within each
subgroup (Ang-2 high HR of 0.93 [95% CI, 0.53–1.65] and
Ang-2 low HR 1.07 [95% CI, 0.52–2.02]). The stratiﬁed PFS
analysis showed similar results.
Table 1. Baseline patient characteristics (n = 189)
Patient
characteristic
Vanucizumab
(n = 94),a n (%)
Bevacizumab
(n = 95), n (%)
Age, years
Median
(range)
64.0 (27–82) 63.0 (29–81)
<65 48.0 (51.1) 53.0 (55.8)
Male sex 56 (59.6) 38 (40.0)
Race
White 90 (95.7) 90 (94.7)
Black 3 (3.2) 1 (1.1)
Asian 0 2 (2.1)
Other 1 (1.1) 2 (2.1)
ECOG
performance
status
0 60 (63.8) 47 (49.5)
1 34 (36.2) 48 (50.5)
Primary tumor
site
Colon 73 (77.7) 77 (81.1)
Rectum 21 (22.3) 18 (18.9)
Left- or
right-sided tumor
Left 67 (75.3) 58 (61.1)
Right 26 (24.7) 37 (38.9)
Primary tumor in
place
Yes 51 (54.3) 48 (50.5)
No 43 (45.7) 47 (49.5)
Metastatic sites
1 34 (36.2) 35 (36.8)
>1 60 (63.8) 60 (63.2)
Adjuvant
treatment
Yes 6 (6.4) 7 (7.4)
No 88 (93.6) 88 (92.6)
Plasma Ang-2
nb 91 93
Median
(range), ng/mL
3.01 (1.1–58.4) 2.93 (1.3–20.8)
KRAS mutation
status
nb 80 81
Mutant 37 (46.3) 45 (55.6)
Wild type 43 (56.8) 36 (44.4)
NRAS mutation
status
nb 80 81
Mutant 13 (16.3) 11 (13.6)
Wild type 67 (83.8) 70 (86.4)
BRAF mutation
status
nb 80 81
(continued)
Table 1. (continued)
Patient
characteristic
Vanucizumab
(n = 94),a n (%)
Bevacizumab
(n = 95), n (%)
Mutant 7 (8.8) 5 (6.2)
Wild type 73 (91.3) 76 (93.8)
aOne patient randomized to the vanucizumab arm received only
chemotherapy before being withdrawn from the study.
bNumber of patients assessed.
Abbreviations: Ang-2, angiopoietin-2; ECOG, Eastern Cooperative
Oncology Group.
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As in the previous study of single-agent vanucizumab
[10], free Ang-2 levels in plasma rapidly decreased after
vanucizumab dosing, whereas levels of total (free plus drug-
bound) Ang-2 increased (Fig. 4). There was no effect of
bevacizumab on soluble Ang-2 levels.
Safety
Adverse events of any grade were reported in all patients,
with a similar proportion of patients experiencing severe
AEs (SAEs) in the vanucizumab and bevacizumab arms,
respectively (Table 2). Similar proportions of patients
experiencing grade ≥3 AEs were also seen across the van-
ucizumab and bevacizumab arms. The most common
grade ≥3 AEs (occurring in ≥5% of patients) were neutrope-
nia, hypertension, diarrhea, and asthenia; a higher propor-
tion (37.6% vs. 18.9%) of patients were diagnosed with
grade ≥3 hypertension (HTN) in the vanucizumab arm com-
pared with in the bevacizumab arm. Sixteen (17.2%) and
ten (10.5%) patients were withdrawn from the study treat-
ment because of AEs in the vanucizumab and bevacizumab
Figure 1. Kaplan-Meier plot of progression-free survival for the intent-to-treat population.
Abbreviation: CI, conﬁdence interval.
All Patients
Adjuvant Therapy (Yes)
No
Yes
Left/Right (inclusive Transverse Colon) sided tumor
Left
Missing
Right
Primary Tumor in Place
No
Yes
ECOG at Baseline
           0
           1
BRAF group
Missing
Other Mutations
V600E
Wild type
RAS group
Missing
Mutant
Wild type
Baseline Risk Factors n
Total
(n = 95)
Bevazicumab
(n = 94)
RO5520985
Events
n
Median n Events
n
Median n Ratio
Hazard
189 50 333 95 40 343 94 0.960
176 47 333 88 40 337 88 1.036
13 3 263 7 0 NE 6 0.000
125 28 333 58 29 343 67 0.963
1 1 53 1 NE
63 22 292 37 10 344 26 0.814
90 26 338 47 12 357 43 0.694
99 24 284 48 28 337 51 1.126
107 26 338 47 21 336 60 0.931
82 24 284 48 19 357 34 1.076
28 6 334 14 10 282 14 1.684
2 1 224 1 0 NE 1 0.000
10 2 284 4 4 394 6 1.265
149 41 309 76 26 343 73 0.834
28 6 334 14 10 282 14 1.684
95 26 333 52 18 327 43 1.110
66 18 248 29 12 386 37 0.523
Better
RO5520985
Better
Bevazicumab
0.10 0.30 1.00 3.00 10.0
Figure 2. Forest plot of progression-free survival hazard ratio by subgroups, including death outside of 30-day window. Mutation
K601Q is artifact only; therefore, it is displayed under “wild type.” Mutation D594G is displayed under “other mutations.”
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NE, not evaluable.
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arms, respectively. Sixteen (17.2%) deaths were reported
in the vanucizumab arm: 13 of these were due to PD,
2 due to SAEs with fatal outcome (intestinal perforation
and cardiac arrest). In the bevacizumab arm, 21 deaths
(22.1%) were reported, including 12 due to PD and 2 due
to SAEs with fatal outcome (septic shock and intestinal
perforation). Other adverse events identiﬁed as being of
special interest (Table 3) revealed that a higher proportion
(38.9%) of patients in the bevacizumab arm experienced
hemorrhages versus the vanucizumab arm (24.7%); most
of these events were grade 1–2. Eleven patients (11.9%) in
the vanucizumab arm and nine patients (9.5%) in the
bevacizumab arm experienced grade 3–4 venous (6.5%
vs. 2.1%) or arterial (1.1% vs. 3.2%) thromboembolic
events. Thirteen (14%) patients in the vanucizumab arm
had peripheral edema (all grade 1–2), compared with ﬁve
(5.3%) in the bevacizumab arm. The proportion of patients
with gastrointestinal perforations (including GI ﬁstula and
abdominal abscess) was comparable across the treatment
arms: ten patients (10.7%) in the vanucizumab arm (GI
perforation [n = 8], GI ﬁstula [n = 1], abdominal abscess
[n = 1]) and eight patients (8.4%) in the bevacizumab arm
(n = 6, 2, and 0).
Three patients developed antidrug antibodies (ADAs) to
vanucizumab after treatment (two in the safety lead-in and
one in the randomized portion). Four patients presented
ADA titers before start of dosing, three of whom were ADA
negative after treatment.
DISCUSSION
Antiangiogenetic agents targeting the VEGF-A–VEGFR path-
way are currently the standard of care in patients with mCRC
[14]. Angiopoetin-2 biology appears VEGF-A dependent and
Figure 3. Kaplan-Meier plot of progression-free survival by plasma angiopoietin-2 baseline levels.
Figure 4. Free and total angiopoietin-2 plasma levels.
Abbreviations: ANG2, angiopoietin-2; BL, baseline; PI, postinfusion.
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downregulated in response to anti–VEGF-A therapy [15];
indeed, in patients receiving bevacizumab-containing treat-
ment, low Ang-2 baseline levels correlated with better PFS
and OS [15, 16]. These observations suggested that Ang-2
suppression may be a predictor of beneﬁt from an anti
−VEGF-A containing therapy but also underscored the
potential value of simultaneous targeting of VEGF-A and
Ang-2 [17–19]. The McCAVE trial demonstrates that
vanucizumab/mFOLFOX-6 treatment was associated with
modulation of the primary target Ang-2 and systemic expo-
sures of vanucizumab/mFOLFOX-6, consistent with those
previously reported [10, 12, 20]. However, our results found
no improvement in either PFS or ORR for vanucizumab com-
pared with bevacizumab in patients with mCRC treated in
combination with mFOLFOX-6. Moreover, exploratory bio-
marker analysis revealed no patient subgroups that would
be likely to beneﬁt from the dual Ang-2–VEGF inhibition. To
this point and consistent with recent ﬁndings from other tri-
als exploring the angiopoietin-Tie2 signaling pathway in
mCRC, soluble Ang-2 levels at baseline were prognostic in
both arms but not predictive for treatment response to van-
ucizumab [21, 22]. Likewise, other prognostic factors, includ-
ing RAS and BRAF mutation status and tumor sidedness,
were largely balanced between arms and did not result in
signiﬁcantly different PFS outcomes across treatment arms.
The overall treatment outcomes in both arms also matched
the historical performance of front-line bevacizumab/
mFOLFOX-6 [23, 24], thereby making it highly implausible
that the therapeutic potency of vanucizumab was con-
founded by the study conduct adversely interfering with
delivery or efﬁcacy of the regimens. Similarly, other emerg-
ing antiangiogenic approaches to potentiate the anti–VEGF-
A effect of bevacizumab in the ﬁrst-line setting of mCRC by
targeting the mesenchymal-epithelial transition receptor
with onartuzumab [25] or the vascular-restricted, extracellu-
lar matrix protein epidermal growth factor-like domain 7 with
parsatuzumab [26] were also unsuccessful.
The overall incidence of AEs, grade ≥3 AEs, serious AEs,
and AEs leading to discontinuation were similar for both
treatment arms. No new safety signals were identiﬁed for
vanucizumab. The distinct toxicities in the vanucizumab arm
matched those reported in previous studies exploring van-
ucizumab as a single agent [10]. Consistent with its mode of
action, peripheral edema formation (all grade ≤2) was more
frequent in patients receiving vanucizumab/mFOLFOX-6,
thereby also supporting respective observations with other
selective inhibitors of the angiopoietin-Tie2 axis [22, 27,
28]. Furthermore, the incidence of HTN grade 3–4 was dou-
bled in the vanucizumab arm and appeared to be mainly
induced by the VEGF-A inhibitory component of the
bispeciﬁc antibody given at a biweekly dose of 2,000 mg
(or 30 mg/kg). HTN is a common complication of anti–
VEGF-A treatment that appears to depend on dose, tumor
type, and interaction with other antineoplastic drugs [29,
30]. Bevacizumab added to ﬁrst-line chemotherapy in mCRC
is associated with HTN grade 3–4 ranging from 3% to 25%
[23, 31, 32], with highest incidence rates being reported for
high dose bevacizumab at 10 mg/kg q2w [33]. On the con-
trary, blocking the angiopoietin-Tie2 signaling pathway in
combination with low-dose bevacizumab (7.5 mg/kg q3w)
or chemotherapy in the setting of ﬁrst- and second-line
mCRC did not result in greater incidence of high-grade HTN
[22, 34]. The incidence rates of GI perforations (including GI
ﬁstula and abscess) were similar in the two treatment arms
Table 2. Adverse events including grade ≥3 AEs with an
incidence of ≥5% in either arm
Adverse event
Vanucizumab
(n = 93), n (%)
Bevacizumab
(n = 95), n (%)
Patients with any AEs 93 (100) 95 (100)
AEs (any grade) 1,734 (100) 1,928 (100)
AEs leading to
discontinuation of
vanucizumab or
bevacizumab
22 (23.7) 17 (17.9)
SAEs 41 (44.1) 40 (42.1)
Death (including due to
PD)
16 (17.2) 21 (22.1)
NCI CTCAE v.4.03
grade ≥3 AEs
78 (83.9) 78 (82.1)
Arterial hypertension 35 (37.6) 18 (18.9)
Neutropenia 28 (30.1) 34 (35.8)
GI perforation 10 (10.7) 8 (8.4)
Thromboembolism 7 (7.6) 5 (5.3)
Asthenia 6 (6.5) 6 (6.3)
Diarrhea 5 (5.4) 11 (11.6)
Abbreviations: AE, adverse event; GI, gastrointestinal; NCI CTCAE,
National Cancer Institute Common Terminology Criteria for Adverse
Events; PD, progressive disease; SAE, severe adverse event.
Table 3. Adverse events of special interest
Adverse event
Vanucizumab
(n = 93), n (%)
Bevacizumab
(n = 95), n (%)
Any
grade ≥G3 AEs
Any
grade ≥G3 AEs
Patients with
any AEs of special
interest
79 (84.9) 52 (56.0) 69 (72.6) 31 (32.7)
Gastrointestinal
perforation
10 (10.7) 10 (10.7) 8 (8.4) 8 (8.4)
Hemorrhage 23 (24.7) 2 (2.2) 37 (38.9) 1 (1.1)
Arterial
hypertension
41 (44.1) 35 (37.6) 27 (28.4) 18 (18.9)
Thromboembolism 11 (11.9) 7 (7.6) 9 (9.5) 5 (5.3)
ATE 1 (1.1) 1 (1.1) 4 (4.2) 3 (3.2)
VTE 10 (10.8) 6 (6.5) 5 (5.3) 2 (2.1)
Congestive heart
failure
1 (1.1) 0 0 0
Peripheral edema 13 (14.0) 0 5 (5.3) 0
Proteinuria 12 (12.9) 0 9 (9.5) 0
Wound healing 2 (2.2) 0 4 (4.2) 1 (1.1)
Neutropenia 40 (43.0) 28 (30.1) 43 (45.3) 34 (35.8)
Infusion related
reaction
19 (20.4) 4 (4.3) 12 (12.6) 2 (2.1)
Abbreviations: AE, adverse event; ATE, arterial thromboembolism;
G3, grade 3; VTE, venous thromboembolism.
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but higher than previously reported with bevacizumab in
mCRC [23, 35]. The exact reason for this is unknown but
likely related to the presence of primary tumors in place for
the majority of affected patients or other known risk factors
such as prior radiotherapy, intestinal stent implants, and/or
recent colonoscopy [36, 37].
CONCLUSION
In conclusion, and by demonstration of Ang-2 target modula-
tion and adequate systemic exposure of vanucizumab, our
data suggest that additional Ang-2 inhibition does not provide
additional beneﬁt over anti–VEGF-A blockade alone when
added to standard chemotherapy for ﬁrst-line treatment of
mCRC. As a result, further clinical development of the dual
VEGF-A–Ang-2 inhibitor vanucizumab was discontinued.
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